MX380201B - Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata. - Google Patents
Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata.Info
- Publication number
- MX380201B MX380201B MX2018012564A MX2018012564A MX380201B MX 380201 B MX380201 B MX 380201B MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 380201 B MX380201 B MX 380201B
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- progression
- prevent
- reduce
- chain peptide
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 4
- 230000001537 neural effect Effects 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un péptido aislado que comprende la secuencia de aminoácidos en la SEQ ID NO.66 para usarse para reducir la incidencia de cáncer de próstata detectado clínicamente en un mamífero, en donde, el péptido está adaptado para ser administrable a la parte central de la próstata donde el cáncer es menos común, y el péptido aislado reduce la incidencia del cáncer de próstata detectado clínicamente en una cantidad mayor que 15% en comparación con la administración de un placebo a mamíferos susceptibles de desarrollar cáncer de próstata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/185,344 US10183058B2 (en) | 2016-06-17 | 2016-06-17 | Method of preventing or reducing the progression of prostate cancer |
| PCT/IB2017/053626 WO2017216779A1 (en) | 2016-06-17 | 2017-06-19 | Neural thread peptide for preventing or reducing the progression of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012564A MX2018012564A (es) | 2019-02-13 |
| MX380201B true MX380201B (es) | 2025-03-12 |
Family
ID=59315668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012564A MX380201B (es) | 2016-06-17 | 2017-06-19 | Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183058B2 (es) |
| EP (1) | EP3432907B1 (es) |
| JP (1) | JP6883048B2 (es) |
| KR (1) | KR102169213B1 (es) |
| CN (2) | CN116785403A (es) |
| AU (1) | AU2017283820B2 (es) |
| BR (1) | BR112018071118A2 (es) |
| CA (1) | CA3020252C (es) |
| MX (1) | MX380201B (es) |
| NZ (1) | NZ746758A (es) |
| RU (1) | RU2719598C1 (es) |
| WO (1) | WO2017216779A1 (es) |
| ZA (1) | ZA201806469B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| CN120037352B (zh) * | 2025-04-23 | 2025-08-22 | 广州飞来爱生命科技有限公司 | 一种脐带间充质干细胞制剂及其在治疗前列腺疾病的用途 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| US4457489A (en) | 1981-07-13 | 1984-07-03 | Gilmore Samuel E | Subsea fluid conduit connections for remote controlled valves |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| CA1310924C (en) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| EP0378924B1 (en) | 1988-12-21 | 1996-11-13 | The General Hospital Corporation | Detection of neurological disease or dysfunction |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| JPH06256387A (ja) | 1991-06-14 | 1994-09-13 | Suetsuna Yoko | 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤 |
| KR100392244B1 (ko) | 1993-04-20 | 2003-11-28 | 더 제너럴 호스피탈 코포레이션 | 신경사단백질유전자발현및알쯔하이머병의검출 |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| JPH11506722A (ja) | 1995-06-07 | 1999-06-15 | ベイラー・カレッジ・オブ・メディスン | 細胞に核酸を送達するための核酸運搬体 |
| BR9711795A (pt) | 1996-03-26 | 2000-06-06 | Razvant T Radulescu | Peptìdeos tendo propriedades antiproliferativas |
| US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
| AU749348B2 (en) | 1997-02-26 | 2002-06-27 | General Hospital Corporation, The | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
| AU9655698A (en) | 1997-10-10 | 1999-05-03 | Astra Aktiebolag | Synthetic genes with immunomodulatory effects |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| AU3517000A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| JP2002543764A (ja) | 1999-03-19 | 2002-12-24 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 46個のヒト分泌タンパク質 |
| EP1171462A2 (en) | 1999-03-26 | 2002-01-16 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| JP2002539842A (ja) | 1999-03-26 | 2002-11-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 45個のヒト分泌タンパク質 |
| EP1220947A2 (en) | 1999-03-26 | 2002-07-10 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸 |
| WO2002000718A2 (en) | 2000-06-26 | 2002-01-03 | Millennium Pharmaceuticals, Inc. | A human calcium channel protein and uses thereof |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| CA2325666A1 (fr) | 2000-12-01 | 2002-06-01 | Institut Pasteur | Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques |
| US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| DE60222745T2 (de) | 2001-03-08 | 2008-07-10 | Nymox Pharmaceutical Corp., St. Laurent | Verwendung von neurofilamentproteinen zur behandlung von tumoren |
| JP2004529179A (ja) | 2001-05-16 | 2004-09-24 | ナイモックス コーポレーション | 神経線維タンパク質のセグメントを使用する細胞死の予防法 |
| BR0209990A (pt) | 2001-05-25 | 2004-06-29 | Nymox Corp | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células |
| DE60217507T2 (de) | 2001-07-19 | 2007-11-15 | Nymox Corp., Saint-Laurent | Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern |
| CN100432103C (zh) * | 2001-07-19 | 2008-11-12 | 尼莫克斯股份有限公司 | 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽 |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| WO2005113720A2 (en) | 2004-05-19 | 2005-12-01 | Auburn University | A strategy for designing patient-specific anti-cancer drugs |
| PL1994152T3 (pl) * | 2006-02-28 | 2013-05-31 | Nymox Corp | Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek |
| EA200801942A1 (ru) * | 2006-03-10 | 2009-02-27 | Наймокс Корпорейшн | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| EP2332560A1 (en) * | 2009-12-14 | 2011-06-15 | Universite D'angers | Use of a neurofilament peptide for the treatment of glioma |
| US9243035B2 (en) | 2013-11-26 | 2016-01-26 | Nymox Corporation | Peptides effective in the treatment of conditions requiring the removal or destruction of cells |
| US9856722B2 (en) | 2014-03-14 | 2018-01-02 | General Electric Company | Methods and systems for controlling voltage switching |
| WO2016008051A1 (en) * | 2014-07-15 | 2016-01-21 | Mcmaster University | Contactin-1 (cntn1) for use in methods of diagnosis and treatment of prostate cancer |
| US20160215031A1 (en) | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
| JP6256387B2 (ja) | 2015-03-09 | 2018-01-10 | 株式会社豊田自動織機 | 電動圧縮機 |
-
2016
- 2016-06-17 US US15/185,344 patent/US10183058B2/en active Active
-
2017
- 2017-06-19 WO PCT/IB2017/053626 patent/WO2017216779A1/en not_active Ceased
- 2017-06-19 CN CN202310983960.3A patent/CN116785403A/zh active Pending
- 2017-06-19 AU AU2017283820A patent/AU2017283820B2/en not_active Ceased
- 2017-06-19 CA CA3020252A patent/CA3020252C/en active Active
- 2017-06-19 BR BR112018071118-7A patent/BR112018071118A2/pt not_active Application Discontinuation
- 2017-06-19 KR KR1020187029630A patent/KR102169213B1/ko not_active Expired - Fee Related
- 2017-06-19 EP EP17737874.2A patent/EP3432907B1/en active Active
- 2017-06-19 JP JP2018550509A patent/JP6883048B2/ja not_active Expired - Fee Related
- 2017-06-19 MX MX2018012564A patent/MX380201B/es unknown
- 2017-06-19 CN CN201780023451.9A patent/CN109310732B/zh not_active Expired - Fee Related
- 2017-06-19 NZ NZ746758A patent/NZ746758A/en not_active IP Right Cessation
- 2017-06-19 RU RU2018137821A patent/RU2719598C1/ru active
-
2018
- 2018-09-28 ZA ZA201806469A patent/ZA201806469B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017283820A1 (en) | 2018-10-18 |
| RU2719598C1 (ru) | 2020-04-21 |
| BR112018071118A2 (pt) | 2019-02-26 |
| KR20180124080A (ko) | 2018-11-20 |
| US20170360885A1 (en) | 2017-12-21 |
| CN116785403A (zh) | 2023-09-22 |
| CN109310732A (zh) | 2019-02-05 |
| AU2017283820B2 (en) | 2019-09-26 |
| WO2017216779A1 (en) | 2017-12-21 |
| MX2018012564A (es) | 2019-02-13 |
| CA3020252A1 (en) | 2017-12-21 |
| EP3432907A1 (en) | 2019-01-30 |
| EP3432907B1 (en) | 2019-10-16 |
| NZ746758A (en) | 2022-07-01 |
| JP6883048B2 (ja) | 2021-06-02 |
| JP2019523751A (ja) | 2019-08-29 |
| CN109310732B (zh) | 2023-07-21 |
| CA3020252C (en) | 2022-07-26 |
| ZA201806469B (en) | 2020-11-25 |
| KR102169213B1 (ko) | 2020-10-23 |
| US10183058B2 (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012564A (es) | Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata. | |
| MX2019002698A (es) | Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. | |
| MX391695B (es) | Péptido derivado de una proteína de hebra neural para uso en el tratamiento de desordenes que requieren la destrucción o retiro de células | |
| MX2021002322A (es) | Nuevos metodos. | |
| CL2022002540A1 (es) | Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| MX383809B (es) | Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas. | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| DOP2018000196A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2 | |
| CL2020000440A1 (es) | Composición farmacéutica para el suministro de péptidos. | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| Oikhberg | Greedy algorithm with gaps | |
| HK1249011A1 (zh) | 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法 | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| MX2019010394A (es) | Composiciones y metodos para mejorar la funcion sexual. | |
| NZ750988A (en) | Method of preventing or reducing the incidence of acute urinary retention | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| PH12018501978A1 (en) | Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibody | |
| WO2015183984A3 (en) | Therapeutic compositions including tocopherol and uses thereof | |
| WO2020212514A8 (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer | |
| MX2020004106A (es) | Metodo de tratamiento de trastornos neurodegenerativos. |